RBC Capital cuts Intra-Cellular stock rating, hikes target to $132
RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...
RBC Capital Keeps Their Hold Rating on Headwater Exploration (CDDRF)
RBC Capital analyst Michael Harvey maintained a Hold rating on Headwater Exploration (CDDRF – Research Report) yesterday and set a price target ...
RBC Capital Reaffirms Their Buy Rating on Exchange Income (EIF)
RBC Capital analyst James McGarragle CFA maintained a Buy rating on Exchange Income (EIF – Research Report) yesterday and set a price target of ...
Hot jobs report cements a Fed rate hold this month — and possibly the foreseeable future
A hot jobs report makes it even more likely the Federal Reserve won’t cut rates at its next meeting in January — or for the foreseeable future.
Seeking Alpha1mon
Hexcel upgraded at RBC Capital on relative value
Hexcel (NYSE:HXL) on Thursday was upgraded to Outperform from a previous investment rating of Sector Perform by analysts at RBC Capital Markets ... in a December 19 report.
Times Colonist15d
Five things to watch for in the Canadian business world in the coming week
The CEOs of Canada's biggest banks will speak at the RBC Capital Markets Canadian Bank CEO Conference on Tuesday ...
The Globe and Mail1mon
RBC analyst provides top REIT picks, reasons to be optimistic in the sector for 2025
RBC Capital Markets analyst Pammi Bir summarized a tough year for REITs and reiterated top picks, “The sector’s Q3/24 rally turned out to be a summer fling. Having given back a good portion of ...